Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/06/Derm-Article-Dermatitis-Artefacta-Treatment-web-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/Mukherjee-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/jak-inhibitor-thumbnail2-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/04/Effect-of-Hemodialysis-on-Cutaneous-Manifestations-of-Chronic-Kidney-Disease-Thumbnail-940x564.png)